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Abstract 
Objective: To verify the influence of age on the prognosis of cervix carcinoma. Study design: Five hundred and sixty eight patients 
treated for a FIGO stage IB-IVA with radical irradiation in the Centre Hospitalier Universitaire Vaudois of Lausanne were sub- 
divided according to the following age categories: _<45, 46-60, 61-69 and > 70 years. Taking the 46-60 years age group as the 
reference, the hazard ratios (HR) of death and corresponding 95% confidence intervals (95% CI) were estimated by means of a 
Cox multivariate analysis. Results: The 5-year survival rates were, respectively, 57%, 67%, 60% and 45%. For the youngest women 
the risk of death was significantly increased (HR = 2.00, 95% CI [1.32-3.00]) and was even more accentuated in advanced stages. 
Conclusion: Age under 45 years is a bad prognostic factor in carcinoma of the cervix. 
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1. Introduction 
Several authors have reported that invasive car- 
cinoma of the cervix had a poorer prognosis in younger 
patients than in older ones [1-14]. Others found no 
effect of age [15-23]. The potential difference in survival 
experience depending on age may have implications on 
the therapeutic approach, which so far has not been dif- 
ferentiated. In this report, we analyse a consecutive 
series of patients who attended a major Swiss University 
Hospital. 
2. Patients and methods 
2.1. Database 
From January 1971 to December 1992, 642 con- 
secutive patients with primary FIGO stage IB-IV car- 
cinoma of the cervix were treated in the Centre 
Hospitalier Universitaire Vaudois, Lausanne. Only 568 
of them were considered for the current study. Of the 74 
* Corresponding author, Tel.: +21 3143269; fax: +21 3143263. 
patients excluded, 20 did not receive radiation therapy, 
31 had incomplete baseline data, and 23 were lost to 
follow-up. Patients characteristics are summarized in 
Table 1. Baseline evaluation for FIGO classification 
included pelvic examination under local or general 
anesthesia, cervical biopsies, cystoscopy, rectoscopy, 
chest X-ray, intravenous pyelogram or computerized 
tomography. Variables available on all patients were 
age, FIGO stage, histology, surgery, radiation therapy 
duration and decade of treatment. Age has been sub- 
divided as follows: _<45, 46-60, 61-69 and >70 years. 
The median age is 60 years (range 20-90 years). 
2.2. Surgery 
One hundred and seventy-four patients with stage IB- 
IIA tumor underwent a radical hysterectomy with pelvic 
lymphadenectomy before radiation therapy. 
2.3. Radiation therapy 
Post-operative radiation therapy was decided because 
of positive margins, positive lymph nodes or vascular in- 
vasion. 
0301-2115/96/$15.00 © 1996 Elsevier Science Ireland Ltd. All rights reserved 
SSD1 0028-2243(95)02290-N 
202 Z b2 Delaloye et al. /European Journal of Obstetrics & Gynecology and Reproductive Biology 64 (1996) 201-205 
Table 1 
Patients characteristics 
Age (years) Total 
~45 46-60 61-69 ~ 70 
Decade 
1971-1979 61 (25) 75 (30) 62 (25) 51 (20) 249 (44) 
1980-1989 39 (17) 63 (28) 64(28) 62 (27) 228 (40) 
1990-1992 21 (23) 27 (30) 19 (21) 24 (26) 91 (16) 
FIGO stage 
IB 39 (32) 28 (17) 23 (16) 14 (10) 104(18) 
II 60 (50) 70 (43) 61 (42) 62 (45) 253 (45) 
III 18 (15) 60 (37) 49 (34) 53 (39) 180 (32) 
IV 4 (3) 6 (3) 12 (8) 8 (6) 30 (5) 
Histology 
Squamous cell 104 (86) 142 (87) 129 (90) 119 (88) 494 (88) 
Other 17 (14) 21 (13) 15 (10) 17 (12) 70 (12} 
Surgery 
Yes 63 (52) 55 (33) 35 (24) 21 (15) 174 (31) 
No 58 (48) 110 (67) I10 (76) 116 (85) 394 (69) 
Therapy duration 
<58 days 95 (79) 121 (73) 110 (76) 97 (71) 423 (74) 
:,-58 days 26 (21) 44 (27) 35 (24) 40 (29) 145 (26) 
Number in parentheses is percentage of column 
External radiation therapy was delivered initially with 
a betatron and in subsequent years with a linear ac- 
celerator. The pelvic volume was approached using a 
four-field box technique tailored in function of local ex- 
tent of the tumor. The dose per fraction generally was 
180-200 cGy/fraction, 5 days per week. Reference point 
was ICRU point. Patients with stage IB-IIA received 45 
Gy to the whole pelvis. Patients with non-operable stage 
IIB-IIIB received 45 Gy to the whole pelvis and a 10-15 
Gy boost to one or both parameters. 
Intracavitary curietherapy delivered a boost of 30 Gy 
to point A or 45 Gy to the vaginal cuff (when a hysterec- 
tomy was performed), using an intra-uterine probe or a 
vaginal ovoid. The rectal dose was measured uring the 
insertion of the source and the total rectal dose for the 
whole period of brachytherapy was computed. In the 
first decade (1971-79), low dose-rate curietherapy 
(LDR) was systematically used, whereas from the sec- 
ond decade on all patients were submitted to high dose- 
rate (HDR). The isotope used for LDR was radium, and 
the isotope used for HDR was cesium. 
External radiation therapy and intracavitary 
curietherapy were performed concomitantly (Con) or se- 
quentially (Seq). Sequential curietherapy was given at 
weekly intervals, 5-20 days following completion of ex- 
ternal radiation. From 1990 to 1993, radiation therapy 
was Seq in 94% of the patients. This distribution is less 
homogeneous for decades 1970-79 (2%) and 1980-89 
(36%). 
2.4. Radiation therapy duration 
This included the duration of external radiation thera- 
py, the time interval between the former and 
brachytherapy, and the duration of brachytherapy. 
Therapy duration was calculated in days. Median thera- 
py duration was 44 days. For the purpose of the analy- 
sis, patients were classified according to whether they 
had rather long therapies, taking 58 days (the 75th per- 
centile) as an arbitrary cut-off. It is generally recognized 
that radiation therapy given over extended time interval 
is associated with reduced survival. [24-26]. 
2.5. Stat&tical methods 
The primary endpoint of this study was overall survi- 
val (OS), which was defined as time from beginning of 
radiation therapy to death due to any cause. Survival 
status for all patients was updated during Summer of 
1993. 
Statistical analyses were carried out by means of the 
software package Stata [27]. Survival percentages over 
time have been calculated by the Kaplan-Meier method 
[28] and their corresponding standard errors (S.E.) with 
Greenwood's formula [29]. For univariate analysis of 
OS the P-values from the log-rank test are reported for 
each comparison considered [30]. Estimated hazard 
ratios (HR) of death, with respect to the indicated refer- 
ence group, their 95% confidence intervals (95% C1) and 
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P-values were calculated with multivariate propor- 
tional-hazard-regression-model [31 ]. The following vari- 
ables, coded into binary indicators to reflect the same 
subgroups hown in the tables, were included in the 
multivariate analysis: FIGO stage, histology, surgery, 
duration of therapy and decade of treatment. Values of 
HR greater than unity indicate increased rates of death 
with respect to the chosen reference category. For analy- 
ses other than on OS, chi-squared tests for independence 
have been used [32]. All probability values were for two- 
sided tests. 
For the purpose of the analyses of survival, observa- 
tions have been censored at 5 years in order to limit the 
effect of competing causes of mortality (cause of death 
was not known with certainty) and also to avoid having 
only patients registered uring the earlier periods con- 
tribute to the right tail of the survival curves. Five-year 
survival was considered a relevant endpoint for cervical 
cancer patients. 
3. Results 
As concerns the distribution of various characteristics 
according to age, we have observed a higher percentage 
of stage IB patients in the age group under 45, and a 
decreasing percentage of women having undergone sur- 
gery with increasing age. On the other hand, the fre- 
quency of histologic subtypes and of radiation therapy 
duration was consistent across age groups. Age distribu- 
tion did not vary across decades. 
A total of 71 patients developed pelvic recurrence and 
a total of 101 patients developed istant metastasis. In 
27 women both events have been observed. The 5-year 
survival rates were, respectively, 57 ± 5% for the ___ 45- 
year group, 67 ± 5% for the 46-60-year group, 
60 ± 4% for the 61-69-year group, and 45 ± 5% for 
the _> 70-year group. 
An analysis based on the Cox model including only 
age has been used to estimate the HRs for each age 
group and the results are reported in Table 2. A similar 
analysis has been performed for each of the other avail- 
able variables and only stage was shown to be a 
statistically significant predictor of survival, more ad- 
vanced stages being at higher risk of death. Age being 
the factor of primary interest, amultivariate analysis has 
Table 2 
Univariate analysis of effect of age: hazard ratios (HR) and related 
95% confidence intervals (95% CI) 
Age HR 95% CI P-value 
(years) 
_< 45 1.39 0.93-2.08 0.105 
46-60 Reference group 
61-69 1.28 0.86-1.89 0.219 
> 70 1.77 1.21 -2.58 0.003 
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Table 3 
Multivariate analysis of effect of age: hazard ratios (HR) and related 
95% confidence intervals (95% CI) 
Age HR 95% CI P-value 
(years) 
_<45 2.00 1.32-3.01 <0.001 
46-60 Reference group 
61-69 1.22 0.82-1.80 0.332 
>70 1.62 1.11-2.36 0.13 
See the statistical method section for the variables included in the Cox 
model. Only results concerning age are displayed. 
been performed in order to assess its role allowing for 
the potential confounding effect of the other covariates. 
The results are displayed in Table 3 only for age and 
suggest a U-shaped relationship between increasing age 
and risk of death. In particular, women aged 45 years or 
less were exposed to the highest risk of death, namely 
the double of the risk of the 46-60 years group 
(HR = 2.00, 95% CI [1.32-3.01]). After 60 years, the 
risk of death increased with increasing age, but never 
reached the level observed in the youngest group. The 
role of stage was also confirmed by the multivariate 
analysis. 
We have investigated whether the effect of age was 
constant within each group of women determined by the 
stage of the disease. An exploratory multivariate regres- 
sion has been performed within each stage subgroup in 
order to compare the survival of women aged 45 or less 
to all other. The results are reported in Table 4. Younger 
women were always at a higher isk of death than older 
women, but their risk increased with increasing stage. In 
the subgroup of stage III, women aged 45 or less had a 
more than double risk of death (HR = 2.28, 95% CI 
[1.26-4.11]) than older women. Similarly, in the sub- 
group of stage IV there was an indication of a live-fold 
increase in the risk of death for younger women 
(HR = 5.15, 95% CI [1.21-21.9]). These results have to 
be interpreted with caution due to their exploratory 
Table 4 
Influence of age: multivariate analysis tratified by FIGO stage 
FIGO Age HR 95% CI P-value 
stage (years) 
I -< 45 1.81 0.62-5.24 0.276 
>45 Reference group 
II _< 45 1.45 0.86-2.43 0.159 
> 45 Reference group 
III _<45 2.28 1.26-4.11 0.006 
>45 Reference group 
IV _<45 5.15 1.21-21.9 0.027 
>45 Reference group 
See the statistical methods ection for the variables included in the Cox 
model. Only results concerning age are displayed. 
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nature and to the small size of the groups, particularly 
so for stage IV. 
4. Discussion 
Some authors have reported a positive association 
between age and risk of death, which could not just be 
attributed to the obvious shorter life expectancy of the 
elderly [11. More often, however, a higher risk tbr 
younger women has been observed [1,3,6,13,141. Addi- 
tionally, it has been noted that younger patients with 
early-stage disease survived longer than older patients. 
but this tendency was reversed when the disease was 
advanced [131. Evidence from other studies does not 
consistently point towards an association between age 
and risk of death. [15,23,33,34]. 
Our results suggest that younger women are at in- 
creased risk of death. The observation that this risk in- 
creases when the disease is diagnosed at an advanced 
stage may imply that the disease is more aggressive in 
younger women. In this study, we do not have available 
reliable classification of cause of death and, therefore, 
we cannot assess whether younger women differ from 
older women in this respect. We cannot exclude either 
that our results are biased by the retrospective nature of 
the study and that our observations could be at- 
tributable to some confounders that we have not allow- 
ed for. The age-specific mortality rate of the cervix 
carcinoma for younger women cannot be attributed to 
a new papilloma virus epidemic during the last 20 years, 
since Sebbelov et al. have shown that the proportion of 
HPV positive patients is equal in all age groups [35]. 
Moreover, this age-specific mortality rate cannot be ac- 
counted for by difference in intrinsic radiosensitivity 
[361. Apoptosis and/or Bcl-2 expression, p53 mutations, 
1L-6 autocrine production, and ploidy should be in- 
vestigated to determine the reasons of treatment resis- 
tance [37-43]. The ongoing research on potential 
doubling time (Tpot) in cervical cancer may shed some 
light on this issue [441. The knowledge of all these 
cellular and molecular mechanisms could potentially 
lead to the elaboration of new strategies for therapeutic 
approaches. 
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